Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-90
SponsorRenmin Hospital of Wuhan University

About this trial

The goal of this observational study was to learn about metabolomics profiles in vitreoretinal diseases by nuclear magnetic resonance (NMR)using vitreous fluid. The main question it aimed to answer was abnormal biomarkers for common retinal diseases such as idiopathic macular hole(IMH), diabetic retinopathy(DR) and retinal detachment(RD). Participants would not be subjected to any intervention and the investigators would only collect preoperative information and remaining vitreous samples. The investigators divided the participants into groups with appropriate disease names based on the disease diagnosis, such as IMH group, DR group, and RD group. The MH group was used as a control group, investigators compared other groups to see the metabolomic abnormalities.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Confirmation of IMH diagnosis with concomitant need for PPV surgery;

Confirmation of DR diagnosis with concomitant need for PPV surgery;

Confirmation of RD diagnosis with concomitant need for PPV surgery;

Confirmation of IMM diagnosis with concomitant need for PPV surgery;

Disqualifiers

Diagnosed vitreoretinal disease with no need for PPV surgery;

Previous history of PPV surgery;

Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis;

Combination of serious systemic diseases such as hypertension and diabetes mellitus.

Trial population

The enrolled participants were patients who attended Renmin Hospital of Wuhan University with a confirmed diagnosis of vitreoretinal disease. As a result, most of the participants were residents of Hubei Province, China. It is expected that vitreous fluid samples collected from patients with IMH, DR, RD, IMM, and RVO were 50, 100, 100, 50, and 50, respectively, for a total of 450, with about a mean age of 56 years.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

450 Participants
are grouped into 5 trial groups
Group A: IMH group
Group B: DR group
Group C: RD group
Group D: IMM group
Group E: RVO group

Trial outcomes

Primary outcomes

1

Relative amino acid concentration(Unite: %)

NMR provides spectral data to show the relative concentration of various amino acids, and the use of NMR to measure vitreous humor and compare changes in amino acid content across disease species leads to speculation about biological markers of disease progression.

Time frame
intraoperative

Secondary outcomes

1

Relative concentrations of macromolecules such as glucose and lipids(Unite: %)

Macromolecules such as glucose and lipids also play a role in the metabolism of vitreoretinal diseases, so NMR spectroscopy will be used to show the relative concentration of macromolecules.

Time frame
intraoperative

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.